New Global Marketing Partnership with Ziosoft

RNS Number : 8367I
Medicsight Plc
25 November 2008

Press Release 25 November 2008

Medicsight PLC

("Medicsight" or "the Company")

New Global Marketing Partnership with Ziosoft Unveiled at RSNA 2008

Medicsight PLC (AIM: MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which
assists in the early detection and diagnosis of disease, announces a new global partnership with Ziosoft Inc ("Ziosoft"), a leading
developer of 3D advanced visualization and analysis technology. Combined Ziosoft-Medicsight products for the detection of colorectal polyps
will be distributed through the Ziosoft network.

Both companies are presenting at the 94th Scientific Assembly and Annual Meeting of the Radiological Society of North America, which is
being held in Chicago, 30 November until 5 December 2008. The companies are demonstrating the first results of the partnership at the
Ziosoft booth (�7957).

Ziosoft is a market leader for 3D workstations. In 2007 the company had an install base of more than 1,500 3D systems. The companies
are working together to integrate Medicsight's ColonCAD with Ziosoft's Ziostation, and the product is due for global launch early in 2009.
US launch will follow the product's US FDA clearance, also expected in early 2009.

David Sumner, Chief Executive of Medicsight, said: "The partnership with Ziosoft is part of our ongoing strategy to build a broad base
distribution channel, which will enable us to quickly penetrate global markets. Global demand for CT colonography looks set to increase
dramatically, with clinical evidence such as the recently published US National CT Colonography Trial (ACRIN 6664) demonstrating the
positive benefits of CTC as a screening procedure for the early detection of colorectal cancer."

"This is the ideal time for Ziosoft to partner with Medicsight." said Mark Koeniguer, COO of Ziosoft. "There is great demand from the
radiology community for intelligent software that will increase their productivity. The partnership will enable us to combine our
revolutionary 3D imaging applications with the CAD and image analysis solutions of Medicsight to fulfil our Company's goal, which is to meet
the needs of any hospital."

- ENDS -

For further information:
Medicsight plc
David Sumner +44 (0)20 7605 7950
www.medicsight.com
Nomura Code
Jonathan Senior +44 (0) 20 7776 1219
Juliet Thompson +44 (0) 20 7776 1204

Media enquiries:
Abchurch +44 (0) 20 7398 7700
Heather Salmond
Stephanie Cuthbert +44 (0) 20 7398 7718
Simone Alves +44 (0) 20 7398 7728
stephanie.cuthbert@abchurch-group.com www.abchurch-group.com

About Medicsight
Medicsight PLC is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software
for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the
colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD
software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data.
Medicsight's ColonCAD* and LungCAD* software products are seamlessly integrated with the advanced 3D visualisation workstations of several
industry-leading imaging equipment partners.

About Ziosoft Inc.
Ziosoft, Inc. is a recognised leader in networked advanced visualization and analysis software to benefit physicians, patients, and
healthcare specialists. Ziosoft is dedicated to providing intelligent and intuitive clinical tools across the enterprise. Ziosoft is a
privately held company with locations in Redwood City, CA and Tokyo, Japan. For more information, visit http://www.ziosoftinc.com.

About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing
challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations
generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due
to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious
regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can
be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of
successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to
help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.

About Medicsight's CAD software
Medicsight's ColonCAD* and LungCAD* software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically
highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such
as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The
integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of
demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users
to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product
related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product
development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to
develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.

This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCEAXFLASEPFFE

Medicsight (LSE:MDST)
Historical Stock Chart
From Jun 2024 to Jul 2024